Immunotherapy before surgery for liver cancer with high recurrence risk
Treatments studied
Part of Cancer clinical trials.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have liver cancer that can be surgically removed and has a medium-to-high risk of coming back.
- You must not have received any prior cancer treatment (like chemotherapy, radiation, or other medications).
- Your liver function must be good (Child-Pugh class A) and you must be in generally good health (ECOG 0 or 1).
- You must not have active serious infections, autoimmune diseases, or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.